NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a biopharmaceutical company with a market capitalization of $2.3 billion ...

[52] Findings in FH Patients. To date, there has been no published result on the lipid-modifying effects of new CETP inhibitors in patients with FH. However, there is an ongoing Phase III trial ...

In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering ...

Other companies are continuing to develop CETP inhibitors, including JTT-705, which is being developed jointly by Roche and Japan Tobacco, and Merck's MK-0859 (Table 1). The next step would be to ...

Remember CETP? It was a hot topic in cholesterol-lowering drug development a few years ago, but when Merck & Co finally pulled the plug on anacetrapib five years ago on lacklustre phase 3 data ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $40.88, a high estimate of $48.00, and a low estimate of $36.00. Marking an ...

Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. A Deep Dive into ...

NewAmsterdam is developing obicetrapib, an oral, low-dose, once-daily, and highly selective cholesteryl ester transfer protein (“CETP”) inhibitor, alone or as a fixed-dose combination with ...

The firm says the shares have been down recently on competitive concerns from NewAmsterdam’s (NAMS) CETP inhibitor, obicetrapib, which recently had positive Phase 3 data. However, investors are ...

While the efficiency of PCSK9 mAbs, mipomersen and lomitapide has been demonstrated in FH patients, there has been no completed trial with new CETP inhibitors in FH, but one trial is underway ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...